320093 VO Applied Pharmacogenetics (2011W)
Labels
Details
Language: German
Examination dates
Lecturers
Classes
Currently no class schedule is known.
Information
Aims, contents and method of the course
Assessment and permitted materials
Minimum requirements and assessment criteria
This course is intended to provide insights into the methodology of pharmacogenetics.
The pharmacokinetics of many drugs is affected by activity of specific cytochrom-P450-enzymes. Genotyping of test subjects (the course participants) will be performed by analysing genomic DNA. The polymorphism of cytochrom-P450 2D6 concerning a particular mutation will be determined. The therapeutic relevance of Cytochrome P450 polymorphism will be discussed.
The pharmacokinetics of many drugs is affected by activity of specific cytochrom-P450-enzymes. Genotyping of test subjects (the course participants) will be performed by analysing genomic DNA. The polymorphism of cytochrom-P450 2D6 concerning a particular mutation will be determined. The therapeutic relevance of Cytochrome P450 polymorphism will be discussed.
Examination topics
Reading list
Association in the course directory
A400
Last modified: We 19.08.2020 08:09
" Bimatoprost, a Prostaglandin F2 -derivative, travoprost, a full agonist at the
prostaglandin FP-receptor, and brinzolamide, a topically active inhibitor of
carboanhydrase II, are used to lower the intraocular pressure in chronic open-
angle glaucoma and in ocular hypertension
" Verteporphin, a photosensitizer, which is suited for photodynamic therapy of
chorioidal neo-vascularizations
" Temoporphin, another photosensitizer, is applied in the photodynamic tumour-
therapy, for instance in certain cases of precancerous lesions and malignant
tumours of the skin
" Imiquimod is suited for the local therapy of Condylomata acuminata in the genital
and anal regions
" the immunsuppressive agents Pimecrolimus and Tacrolimus are important
additions to the topical treatment of atopic dermatitis
" Eflornithin, an irreversible inhibitor of the ornithin-decarboxylase, which is
registered for the treatment of hirsutism in the face of women